Ikarovec


Ikarovec develops gene therapies to treat major ophthalmic indications. Its lead program is a multicistronic gene therapy for diabetic macular edema, to IND-enabling studies.

Ikarovec develops gene therapies to treat major ophthalmic indications. Its lead program is a multicistronic gene therapy for diabetic macular edema, to IND-enabling studies.

Company (Alive / Active)

All investors data 3 Investors

Phone:

Fax:



Cambridge,
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Ikarovec $3.3M Feb 5, 2020

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Ikarovec Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors

Board Members

Name Firm
Login to see detailsLifeArc
Login to see detailsUK Innovation & Science Seed Fund
Login to see detailsParkwalk Advisors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)